Evidence map›Paper›PMID 40026259›Full record

SynthesisClinical cardiology2025

Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis.

Abolfazl Sam Daliri, Nima Goudarzi, Arshia Harati, Kourosh Kabir

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abolfazl Sam DaliriMedical Student, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Nima GoudarziMedical Student, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.ORCID http://orcid.org/0000-0002-3368-3042
Arshia HaratiMedical Student, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Kourosh KabirDepartment of Community Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundHeart failure as an advanced cardiac disease has a high incidence and prevalence in all societies nowadays. Many drugs and treatment methods have been discovered for improving heart failure patients' conditions till now in this way melatonin therapy is one of the less-known methods rarely used by clinicians.

methodsTo investigate the positive effect of melatonin on heart failure development, we conducted a systematic review and meta-analysis by searching valid databases with keywords based on the protocol. Based on the eligible criteria, four articles were selected for data synthesis and analysis after scanning the title and/or abstract and reading full-text.

resultsAs a result of analysis, increasing ejection fraction (Mean difference: 2.39 [-1.82, 6.59] p = 0.27), NYHA (New York Heart Association Functional Class) (Odds ratio: 4.84 [1.00, 23.44] p = 0.05), and significant elevation of quality of life (Mean difference: -5.95 [-9.54, -2.35] p = 0.001) were observed. As the effect of melatonin, fatigue, and NT-Pro BNP were reduced but on the contrary sleep quality, appetite, and FMD (Flow-Mediated Dilation) significantly increased.

conclusionThus, melatonin, by increasing psychologic parameters and cardiac potency, could be advised as a novel drug for treatment and palliating heart failure patients.

Indexed as

Heart FailureMelatoninQuality of LifeStroke VolumeVentricular Function, LeftHumansTreatment OutcomeMelatonincardiac potencyejection fractionheart failuremelatoninmeta‐analysisNT‐Pro BNPNYHA function classesQuality of lifestroke volumesystematic review

Identifiers

PMID40026259
PMCPMC11873767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.